STOCK TITAN

Kymera Therapeutics, Inc. reported $39.2M in revenue and $311.4M in net income for fiscal 2025. See the full KYMR financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics plans a series of webcast investor presentations at major healthcare and biopharma conferences throughout September 2026.

(Neutral)
(Neutral)
Tags

Kymera Therapeutics (KYMR) will participate in several investor conferences in September 2026, including events hosted by Wells Fargo, Citi, H.C. Wainwright, Morgan Stanley and Stifel, with scheduled fireside chats and presentations across September 9–24.

Live webcasts and subsequent replays will be accessible via the Investors “News and Events” section of the company’s website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

Recent KYMR history included a 0.2% 24-hour move after the September 1 presentation announcement, wh...
Analysis

Recent KYMR history included a 0.2% 24-hour move after the September 1 presentation announcement, while other events produced mixed outcomes. The scheduled conferences disclose no operating result; moderate short positioning remains a risk context.

Key Figures

Wells Fargo conference: September 9 at 8:00 AM ET Citi summit: September 10 at 11:20 AM ET H.C. Wainwright conference: September 14 at 4:30 PM ET +2 more
5 metrics
Wells Fargo conference September 9 at 8:00 AM ET Wells Fargo 21st Annual Healthcare Conference
Citi summit September 10 at 11:20 AM ET Citi 2026 Biopharma Back to School Summit
H.C. Wainwright conference September 14 at 4:30 PM ET H.C. Wainwright 28th Annual Global Investment Conference
Morgan Stanley conference September 15 at 7:45 AM ET Morgan Stanley 24th Annual Global Healthcare Conference
Stifel forum September 24 at 11:00 AM ET Stifel 2026 Virtual Immunology and Inflammation Forum

Historical Context

5 past events · Latest: Sep 01 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Sep 01 Investor presentations Positive +0.2% Conference presentations on KT-621 data at ERS and EADV congresses.
Aug 05 2Q26 earnings Positive +1.0% Collaboration revenue, lower net loss, cash balance, and pipeline progress were reported.
Jul 28 Earnings scheduling Neutral -0.9% Company scheduled Q2 2026 results and webcast for August 5.
Jul 27 CMO appointment Neutral -3.5% Terence Rooney became CMO as Jared Gollob transitioned to advisor.
Jul 07 Program appointment Positive +3.9% Elizabeth Laws joined to lead KT-621 global program strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, with positive responses to earnings and pipeline-related announcements but negative responses to a scheduling notice and leadership transition.

Key Terms

small molecule degrader
1 terms
small molecule degrader technical
"advancing a new class of oral small molecule degrader medicines"
Small molecule degraders are chemically made drugs that stick to a disease-related protein and then recruit the cell’s natural disposal machinery to break that protein down, rather than just blocking its activity. Think of them like a smart label that tags a faulty machine for removal; for investors, they matter because this approach can target proteins traditional drugs cannot, potentially opening new therapeutic markets and altering a drug candidate’s commercial and development prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: 

  • Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET;
  • Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET;
  • H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 14 at 4:30 PM ET;
  • Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY on September 15 at 7:45 AM ET; and
  • Stifel 2026 Virtual Immunology and Inflammation Forum on September 24 at 11:00 AM ET.

Live webcasts of the events will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events. 

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300


FAQ

What investor conferences will Kymera Therapeutics (KYMR) attend in September 2026?

Kymera Therapeutics will attend the Wells Fargo 21st Annual Healthcare Conference, Citi 2026 Biopharma Back to School Summit, H.C. Wainwright 28th Annual Global Investment Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and the Stifel 2026 Virtual Immunology and Inflammation Forum.

When is Kymera Therapeutics presenting at the Wells Fargo Healthcare Conference in 2026?

Kymera Therapeutics is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference in Boston, Massachusetts on September 9 at 8:00 AM ET.

What is the date and time of Kymera Therapeutics’ session at the Citi 2026 Biopharma Back to School Summit?

Kymera Therapeutics plans to present at the Citi 2026 Biopharma Back to School Summit in New York, New York on September 10 at 11:20 AM ET.

When will Kymera Therapeutics present at the H.C. Wainwright 28th Annual Global Investment Conference?

Kymera Therapeutics is scheduled for a session at the H.C. Wainwright 28th Annual Global Investment Conference in New York, New York on September 14 at 4:30 PM ET.

What is the schedule for Kymera Therapeutics at the Morgan Stanley Global Healthcare Conference 2026?

Kymera Therapeutics expects to participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, New York on September 15 at 7:45 AM ET.

When is Kymera Therapeutics presenting at the Stifel 2026 Virtual Immunology and Inflammation Forum?

Kymera Therapeutics is slated to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24 at 11:00 AM ET.

How can investors access Kymera Therapeutics’ September 2026 conference webcasts and replays?

Live webcasts of Kymera Therapeutics’ September 2026 conference appearances, along with archived replays, will be available in the Investors section of the company’s website under the “News and Events” page.